AstraZeneca (AZ, NASDAQ: AZN), a leading global biopharmaceutical company, is planning to restructure and spin off its county oncology team. The team will be integrated into two divisions: the lung cancer division and the urology, gynecology, and women’s oncology division. This strategic move aims to establish a more direct and efficient “vertically aligned” commercial team structure.
Originally established in 2015, the county oncology team expanded its reach to 1,850 counties across 28 provinces by 2020. The team was formed in response to medical reforms that promoted tiered diagnosis and treatment, shifting from city to county-level healthcare facilities. In November 2021, AstraZeneca reorganized its county-level business, merging its county oncology business into the oncology division and integrating its county-level chronic disease business with retail, community, and “Feiying” business to form a new omnichannel division. The latest restructuring effort is designed to synchronize the development of county markets with the core product markets of AstraZeneca.- Flcube.com
